This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.
The decision from NICE makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy to be recommended for routine use on the NHS. ... Helen Knight, director of medicines evaluation at NICE, said: “I am delighted that we have been able to
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for treating a hereditary form of amyloidosis, the RNA interference (RNAi) ... The decision from NICE makes
Ninlaro with lenalidomide and dexamethasone improved clinical outcomes. Takeda’s Ninlaro (ixazomib) with lenalidomide and dexamethasone has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ... This latest
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2-positive unresectable or metastatic breast ... NICE will then use this data
However, it was not until 2017 that the FDA approved the first DTx to treat disease and NICE only provided its first guidance for a prescription DTx in May 2022.
Boehringer Ingelheim’s Ofev (nintedanib) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of idiopathic pulmonary fibrosis (IPF) in adults with a forced ... NICE estimated that more than 5, 200
More from news
Approximately 439 fully matching, plus 853 partially matching documents found.
Pre-COVID-19, much of this was optional, a nice-to-have; now, it’s critical.
Industry understands that it will not solve this by saying nice words because that doesn’t translate to anything,” she said.
Some formal health technology assessment (HTA) guidance on the use of external controls (ECs) and RWE is available from the UK’s National Institute for Health and Care Excellence (NICE).
rare mutations, under the condition of additional RWE collection for NICE reassessment. ... To support this further, NICE has recently published its Real-World Evidence Framework, a ‘living document’ to facilitate best practice for planning,
OK, this is a massive oversimplification, but you get the point: the public’s opinion of the product and the company really hasn’t been anything but a ‘nice-to-have’.
More from intelligence
Approximately 12 fully matching, plus 143 partially matching documents found.
Care Excellence (NICE) highly specialised technology lead Josie Godfrey (pictured centre left).
He was appointed in April 1999 when NICE was first established under Tony Blair’s ‘New Labour’ government. ... I am delighted that Gill has been appointed as NICE’s next chief executive.
The Association of the British Pharmaceutical Industry (ABPI) has attracted Professor Carole Longson away from the National Institute for Health and Care Excellence (NICE) to be its new chief scientific officer, ... She most recently spent the 18 years
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around
She has over 15 years' experience working in medical education and is a member of the ISMPP Ethics Committee, the NICE Implementation External Reference Group and part of the Royal Berkshire
More from appointments
Approximately 4 fully matching, plus 11 partially matching documents found.
37. While the app is approved for sale in the UK and can be advertised to the public, NICE still argues that there is not yet sufficient evidence for the app ... Published September 10, 2018. Accessed November 4, 2021. Wilkinson E. NICE: More evidence
NHS England’s MedTech funding mandate only covers technologies deemed effective (based on NICE guidance), cost-saving within three years of implementation (based on NICE modelling) and affordable (not exceeding £20 ... The UK Government, NHS and NICE
References. NICE. BNF. Cytotoxic Drugs. Available at: . Accessed November 2022. Cancer.net. What is targeted therapy? Available at: . Accessed November 2022. UptoDate. Overview of therapeutic monoclonal antibodies. Available at: . Accessed November
NICE guidelines are also essential reading. Third, it is important to work with ICSs and the wider clinical community to raise awareness of disease and facilitate best practice.
According to Ross Selby, Head of Global Patient Access at Takeda Oncology via NICE: “Uncertainty is the prime reason that medicines struggle with HTA.
More from PMHub
Approximately 2 fully matching, plus 61 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...